The Evaluation of Clinical Applications for the Detection of the Alzheimer's Disease Biomarker GFAP

Basit Öğe Kaydı
dc.authoridOZKAN, Sibel/0000-0001-7494-3077
dc.authoridOzcelikay, Goksu/0000-0001-7919-3236
dc.authoridCetinkaya, Ahmet/0000-0001-5014-0907
dc.authoridUNAL, Mehmet Altay/0000-0001-8607-5043
dc.authoridKaradurmus, Leyla/0000-0001-9833-9819
dc.authoridOzcan, Burcu/0000-0002-5123-5972
dc.contributor.authorOzcelikay-Akyildiz, Goksu
dc.contributor.authorKaradurmus, Leyla
dc.contributor.authorCetinkaya, Ahmet
dc.contributor.authorUludag, Inci
dc.contributor.authorOzcan, Burcu
dc.contributor.authorUnal, Mehmet Altay
dc.contributor.authorSezgintürk, Mustafa Kemal
dc.date.accessioned2025-01-27T20:29:52Z
dc.date.available2025-01-27T20:29:52Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractOne of the most prevalent neurodegenerative diseases is Alzheimer's disease (AD). The hallmarks of AD include the accumulation of amyloid plaques and neurofibrillary tangles, which cause related secondary diseases, progressive neurodegeneration, and ultimately death. The most prevalent cell type in the human central nervous system, astrocytes, are crucial for controlling neuronal function. Glial fibrillary acidic protein (GFAP) is released from tissue into the bloodstream due to astrocyte breakdown in neurological diseases. Increased levels of GFAP in the serum can function as blood markers and be an effective prognostic indicator to help diagnose neurological conditions early on, from stroke to neurodegenerative diseases. The human central nervous system (CNS) is greatly affected by diseases associated with blood GFAP levels. These include multiple sclerosis, intracerebral hemorrhage, glioblastoma multiforme, traumatic brain injuries, and neuromyelitis optica. GFAP demonstrates a strong diagnostic capacity for projecting outcomes following an injury. Furthermore, the increased ability to identify GFAP protein fragments helps facilitate treatment, as it allows continuous screening of CNS injuries and early identification of potential recurrences. GFAP has recently gained attention due to data showing that the plasma biomarker is effective in identifying AD pathology. AD accounts for 60-70% of the approximately 50 million people with dementia worldwide. It is critical to develop molecular markers for AD, whose number is expected to increase to about 3 times and affect humans by 2050, and to investigate possible targets to confirm their effectiveness in the early diagnosis of AD. In addition, most diagnostic methods currently used are image-based and do not detect early disease, i.e. before symptoms appear; thus, treatment options and outcomes are limited. Therefore, recently developed methods such as point-of-care (POC), on-site applications, and enzyme-linked immunosorbent assay-polymerase chain reaction (ELISA-PCR) that provide both faster and more accurate results are gaining importance. This systematic review summarizes published studies with different approaches such as immunosensor, lateral flow, POC, ELISA-PCR, and molecularly imprinted polymer using GFAP, a potential blood biomarker to detect neurological disorders. Here, we also provide an overview of current approaches, analysis methods, and different future detection strategies for GFAP, the most popular biosensing field.
dc.description.sponsorshipScientific and Technological Research Council of Trkiye (TUBITAK) [20AG003]
dc.description.sponsorshipAhmet Cetinkaya, thanks to his grant from the Scientific and Technological Research Council of Tuerkiye (TUBITAK) under the BIDEB/2218-National Postdoctoral Research Scholarship Program and ARDEB/1004-Center of Excellence Support Program (Project No: 20AG003).
dc.identifier.doi10.1080/10408347.2024.2393874
dc.identifier.issn1040-8347
dc.identifier.issn1547-6510
dc.identifier.pmid39178137
dc.identifier.scopus2-s2.0-85201969896
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1080/10408347.2024.2393874
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23056
dc.identifier.wosWOS:001296762500001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.ispartofCritical Reviews in Analytical Chemistry
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectAlzheimer's disease
dc.subjectcentral nervous system
dc.subjectdiagnostics
dc.subjectglial fibrillary acidic protein
dc.subjectneurodegeneration
dc.titleThe Evaluation of Clinical Applications for the Detection of the Alzheimer's Disease Biomarker GFAP
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu